Steve Harr - 06 Mar 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Reporting relationship: President & CEO, Director
Issuer ticker: SANA
Reported as of: 06 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Mar 2026, 16:16:12 UTC
Prior SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Steve Harr

Key filing fact

Steve Harr filed Form 4 for Sana Biotechnology, Inc. (SANA) on 10 Mar 2026.

Key facts

This page summarizes Steve Harr's Form 4 filing for Sana Biotechnology, Inc. (SANA).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Mar 2026, 16:16.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001627387 Primary reporting owner

Harr Steve

Relationship: President & CEO, Director
Address: C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Steve Harr
Signature date: 10 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SANA transaction

Common Stock

Options Exercise

Transaction value
Shares: +41,666
Change %: +0.53%
Price: $0.000000^*
Shares after: 7,918,596
Date: 06 Mar 2026
Ownership: Direct

SANA transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %: +0.63%
Price: $0.000000^*
Shares after: 7,968,596
Date: 07 Mar 2026
Ownership: Direct

SANA transaction

Common Stock

Tax liability

Transaction value
Shares: -11,526
Change %: -0.14%
Price: $3.13^*
Shares after: 7,957,070
Date: 09 Mar 2026
Ownership: Direct

SANA transaction

Common Stock

Tax liability

Transaction value
Shares: -12,819
Change %: -0.16%
Price: $3.10^*
Shares after: 7,944,251
Date: 09 Mar 2026
Ownership: Direct

SANA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 682,500
Date: 06 Mar 2026
Ownership: Held by Harr Family Irrevocable Trust of 2015 dtd 12/28/2015

SANA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 167,000
Date: 06 Mar 2026
Ownership: Held by Brian L Harr TTEE CCH Irrevocable Trust U/A DTD 03/25/2021
Footnotes: F1

SANA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 167,000
Date: 06 Mar 2026
Ownership: Held by Brian L Harr TTEE JOH Irrevocable Trust U/A DTD 03/25/2021
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SANA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -41,666
Change %: -25%
Price: $0.000000^*
Shares after: 125,001
Date: 06 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,666
Exercise price
Footnotes: F2, F3

SANA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -50,000
Change %: -33%
Price: $0.000000^*
Shares after: 100,000
Date: 07 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Brian L. Harr is the trustee of these trusts, whose sole beneficiaries are members of the reporting person's immediate family.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

Footnote F3

The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Footnote F4

The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.